Bio-Rad Labs (BIO) Acquires Celsee

Bio-Rad Laboratories, Inc. (NYSE: BIO), a global leader of life science research and clinical diagnostic products, today announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Terms of the acquisition were not disclosed. Bio-Rad will discuss the acquisition in more detail during its first-quarter 2020 financial results conference call.

Celsee’s Genesis System offers a practical, scalable, and efficient approach to accurately analyze single cells. Using the Genesis System, scientists can isolate, analyze, and interpret cellular behavior and collect cell-based information for improved results in applications such as single-cell cytometry, single-cell transcriptomics, single-cell multiomics, rare-cell enrichment and enumeration, and immune monitoring. The system can scale from hundreds of thousands to millions of cells for genomic and proteomic applications and can enrich or monitor circulating tumor cells to determine disease progression and therapeutic response.

“We are pleased to have Celsee join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO. “Their innovative products and technologies will extend our reach into the rapidly growing world of precision medicine and single-cell analysis, both of which offer enhanced insight into disease, diagnosis, and treatment.”

Founded in 2011 and based in Ann Arbor, Michigan, Celsee’s customers include research, translational, and biopharma laboratories worldwide.

You May Also Be Interested In

• Trustar Bank to acquire Forbright Bank branches for $750M in deposits
• Synaptics CFO resigns amid pending ON Semiconductor merger
• Evolution Petroleum closes $16M Midland Basin royalty acquisition